Colleen Kusy
Stock Analyst at Baird
(1.74)
# 3,331
Out of 5,005 analysts
50
Total ratings
34.09%
Success rate
-9.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $11.41 | +110.34% | 5 | Oct 3, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $9 | $1.98 | +354.55% | 1 | Aug 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $47 → $50 | $23.80 | +110.08% | 12 | Jul 18, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $105 → $112 | $84.22 | +32.99% | 2 | Jun 25, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $19.61 | +165.17% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $4.14 | +44.93% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $17.57 | +133.35% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.64 | +265.85% | 5 | Dec 5, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $15.89 | +309.06% | 2 | Nov 13, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $100 → $75 | $8.28 | +805.80% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $11.57 | +116.17% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $6.38 | +3,191.54% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.34 | +1,352.99% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $2.06 | +11,065.05% | 1 | Nov 2, 2021 |
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $11.41
Upside: +110.34%
Climb Bio
Aug 15, 2025
Initiates: Outperform
Price Target: $9
Current: $1.98
Upside: +354.55%
Apellis Pharmaceuticals
Jul 18, 2025
Maintains: Outperform
Price Target: $47 → $50
Current: $23.80
Upside: +110.08%
Nuvalent
Jun 25, 2025
Maintains: Outperform
Price Target: $105 → $112
Current: $84.22
Upside: +32.99%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $19.61
Upside: +165.17%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $4.14
Upside: +44.93%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $17.57
Upside: +133.35%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.64
Upside: +265.85%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $15.89
Upside: +309.06%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $100 → $75
Current: $8.28
Upside: +805.80%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $11.57
Upside: +116.17%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $6.38
Upside: +3,191.54%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.34
Upside: +1,352.99%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $2.06
Upside: +11,065.05%